Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people notice a reduction in hunger within the first one to four weeks of starting Mounjaro, though the timing varies considerably from person to person. Some feel a difference by day three or four of their first pen; others don't notice the appetite shift clearly until they move to a higher dose. Mounjaro (tirzepatide) works by activating both GIP and GLP-1 gut-hormone receptors, which together slow gastric emptying and signal fullness to the brain — but how quickly your body responds to those signals is genuinely individual. As a prescription-only medicine, Mounjaro is prescribed after a clinical assessment, and your prescriber is best placed to interpret what you're experiencing as treatment progresses. Find out more about how Mounjaro works as a weight-management treatment.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
This is the question behind most searches on this topic. You've started Mounjaro, a week or two has passed, and you're not sure whether the absence of obvious appetite change means the treatment isn't working, or whether you simply haven't reached the point where it does. That uncertainty is worth sitting with carefully, because the answer changes what you should do next.
The 2.5mg starting pen exists for one reason: tolerability. Your digestive system needs time to adjust to slowed gastric emptying, and beginning at a low dose reduces the nausea and stomach discomfort that can otherwise make the early weeks miserable. At 2.5mg, the appetite-suppressing effect is often subtle. That's by design, not failure. Many people describe the hunger shift as gradual, meals feel slightly more filling, the urge to snack after dinner fades, portion sizes shrink without much conscious effort. You might notice it first on a Wednesday evening rather than the morning after your injection.
If you're still finding hunger unchanged after four weeks at 2.5mg, the expected next step is a dose increase, reviewed by your prescriber. Still feeling hungry at week two is common enough that it has its own clinical context, the short answer is that it doesn't mean the medicine isn't doing anything.
The decision you face is: hold, discuss, or escalate. That decision belongs with your prescriber. Changing your own dose timing or frequency isn't something to attempt independently.
Tirzepatide's effect on hunger isn't a switch, it's a gradient. After your first injection, blood concentrations rise over the following 24 to 48 hours and then plateau. The half-life is roughly five days, so by the time you inject your second dose, some of the first is still active. With each subsequent dose, the steady-state concentration builds, and most people find the appetite effect strengthens in parallel.
The question of how long Mounjaro takes to work overall involves two separate timelines: when you start to feel less hungry (often weeks one to four) and when weight loss becomes clearly measurable on the scales (more typically weeks four to eight, sometimes later). These don't always align. Someone who notices strong appetite suppression early may lose weight more slowly than the trial averages suggest; someone who notices very little in the first month may still be losing body mass. The NHS's guidance on tirzepatide notes that individual response varies and that clinical review should assess progress over time, not week by week.
By week three, many people describe a noticeable shift in their relationship with food, not an absence of hunger exactly, but a reduced urgency. A biscuit left on a plate. A smaller portion that feels like enough. The kind of signal your body was presumably sending before, just quieter. Week three is often a turning point for people who had a slow start.
Several things influence how quickly and strongly appetite suppression develops. Body weight at baseline matters: a higher starting weight means a larger volume of distribution for the drug, which can mean a less pronounced early effect at low doses. Metabolic factors, gut motility and individual hormone sensitivity all play a role. The dose level is probably the biggest single variable, in clinical trials, the appetite and weight-loss effects of tirzepatide scaled meaningfully with dose, which is why the longer-term results data mostly comes from higher maintenance doses.
What you're eating alongside treatment also shapes what you notice. Mounjaro isn't a metabolic override, the appetite signal it amplifies still interacts with your usual food environment. High-fat, high-sugar foods that were engineered to override satiety signals can partially blunt the effect. This is part of why NICE's appraisal of tirzepatide specifies it should be used alongside a reduced-calorie diet and increased physical activity, not as a standalone fix.
The right moment to contact your prescriber is if: you're at week four or beyond at a given dose and hunger hasn't changed; you're experiencing side effects that make eating or hydrating difficult; or you're unsure whether your response is typical. The broader picture of when Mounjaro's effects become noticeable covers both appetite and energy changes, which sometimes diverge. At nume, a real clinician reads your follow-up notes (not software) and aftercare is available seven days a week. Speak to our prescribers if you're unsure where you are in your treatment journey.
One thing our prescribers hear regularly: patients who stopped treatment because hunger hadn't changed by week two, and who later learned they were on the cusp of responding. If you're in that position, it's worth the conversation before any decisions about stopping Mounjaro. A brief check-in costs nothing; stopping too early forfeits weeks of adjustment.
For more on the financial side of treatment, Mounjaro pricing is covered separately, including what a legitimate private prescription should include.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.